Anavex announces issuance of new U.S. patent expanding ANAVEX2-73

Anavex Life Sciences announced it was granted a new U.S. Patent No. 11,622,955 entitled "SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY," from the United States Patent and Trademark Office, USPTO, expanding Anavex’s coverage of treatment methods for ANAVEX(R)2-73, to the treatment of systolic hypertension, or lowering systolic blood pressure. "We are extremely pleased with the expansion of the patent portfolio for ANAVEX(R)2-73 for the indication of hypertension which affects nearly half of adults in the United States, especially since elevated systolic blood pressure is a major health economy problem within our aging society," said Christopher Missling, PhD, President and Chief Executive Officer of Anavex. "This new patent will add to our already robust patent portfolio relating to ANAVEX2-73, and further demonstrate our strong overall commitment to protecting the full range of commercial opportunities of our product portfolio." Anavex’s newest patent will be expected to remain in force at least until November 2038, not including any patent term extensions. The new patent expands existing protections for the use of ANAVEX(R)2-73 in treating neurodegenerative disorders to the new use for treating systolic hypertension in addition to existing antihypertension therapy. The market for uncontrolled hypertension is 37 million adults in the U.S. alone.